NASDAQ: ICCCImmucell Corp Stock
$4.77-0.29 (-5.73%)
Updated May 31, 2023
ICCC Price
$4.77
Fair Value Price
$5.17
Market Cap
$36.95M
52 Week Low
$4.26
52 Week High
$9.61
P/E
-7.01x
P/B
1.31x
P/S
2.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.01M
Earnings
-$5.32M
Gross Margin
30.3%
Operating Margin
-33.18%
Profit Margin
-33.2%
Debt to Equity
0.53
Operating Cash Flow
-$5M
Beta
0.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ICCC Overview
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ICCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICCC ($4.77) is undervalued by 7.73% relative to our estimate of its Fair Value price of $5.17 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ICCC ($4.77) is not significantly undervalued (7.73%) relative to our estimate of its Fair Value price of $5.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ICCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ICCC due diligence checks available for Premium users.
Be the first to know about important ICCC news, forecast changes, insider trades & much more!
ICCC News
Valuation
ICCC fair value
Fair Value of ICCC stock based on Discounted Cash Flow (DCF)
Price
$4.77
Fair Value
$5.17
Undervalued by
7.73%
ICCC ($4.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ICCC ($4.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ICCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ICCC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.01x
Industry
11.81x
Market
54.01x
ICCC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.31x
Industry
5.14x
ICCC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ICCC's financial health
Profit margin
Revenue
$3.4M
Net Income
-$2.3M
Profit Margin
-67.2%
ICCC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ICCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$43.1M
Liabilities
$15.0M
Debt to equity
0.53
ICCC's short-term assets ($12.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICCC's short-term assets ($12.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICCC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ICCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
-$682.2k
Financing
$748.6k
ICCC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ICCC vs Biotech Stocks
Immucell Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.